BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BicycleTx Limited readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies BicycleTx Limited's drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04180371-2421@assetmemo.bio
DTSTAMP:20261121T010142Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nuzefatide pevedotin: Phase 1/2 readout est. (NCT04180371)
DESCRIPTION:Nuzefatide pevedotin\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Study BT5528-100 in Patients With Advanced Solid Tumors Associated
  With EphA2 Expression\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nuzefatide-pevedotin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT041803
 71
URL:https://assetmemo.bio/drug/nuzefatide-pevedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06225596-2820@assetmemo.bio
DTSTAMP:20261121T010142Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Zelenectide pevedotin: Phase 2 readout est. (NCT06225596)
DESCRIPTION:Zelenectide pevedotin\, phase 2\, Urothelial Carcinoma.\nStudy:
  Study BT8009-230 in Participants With Locally Advanced or Metastatic Urot
 helial Cancer (Duravelo-2)\nEstimated primary completion: March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/zelenectide-pevedotin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0622559
 6
URL:https://assetmemo.bio/drug/zelenectide-pevedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840483-2820@assetmemo.bio
DTSTAMP:20261121T010142Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Zelenectide pevedotin: Phase 2 readout est. (NCT06840483)
DESCRIPTION:Zelenectide pevedotin\, phase 2.\nStudy: Study of Zelenectide P
 evedotin in Participants With Advanced Breast Cancer\nEstimated primary co
 mpletion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zelenectide-pevedotin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06840483
URL:https://assetmemo.bio/drug/zelenectide-pevedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07450859-2421@assetmemo.bio
DTSTAMP:20261121T010142Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Nuzefatide pevedotin: Phase 2 readout est. (NCT07450859)
DESCRIPTION:Nuzefatide pevedotin\, phase 2\, Pancreatic Ductal Adenocarcino
 ma.\nStudy: A Study of Nuzefatide Pevedotin (BT5528) in Patients With Meta
 static Pancreatic Ductal Adenocarcinoma (PDAC)\nEstimated primary completi
 on: March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nuzef
 atide-pevedotin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07450859
URL:https://assetmemo.bio/drug/nuzefatide-pevedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07681674-2421@assetmemo.bio
DTSTAMP:20261121T010142Z
DTSTART;VALUE=DATE:20300530
DTEND;VALUE=DATE:20300531
SUMMARY:Nuzefatide pevedotin: Phase 2 readout est. (NCT07681674)
DESCRIPTION:Nuzefatide pevedotin\, phase 2.\nStudy: Bicycle Continued Acces
 s Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Pr
 oduct\nEstimated primary completion: 30 May 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nuzefatide-pevedotin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07681674
URL:https://assetmemo.bio/drug/nuzefatide-pevedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
